Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 528

1.

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.

Yin OQP, Antman EM, Braunwald E, Mercuri MF, Miller R, Morrow D, Ruff CT, Truitt K, Weitz JI, Giugliano RP.

Circulation. 2018 Jul 2. pii: CIRCULATIONAHA.118.033933. doi: 10.1161/CIRCULATIONAHA.118.033933. [Epub ahead of print]

PMID:
29967197
2.

Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).

Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP.

Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e003998. doi: 10.1161/CIRCOUTCOMES.117.003998.

PMID:
29748353
3.

Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.

Douketis JD, Murphy SA, Antman EM, Grip LT, Mercuri MF, Ruff CT, Weitz JI, Braunwald E, Giugliano RP.

Thromb Haemost. 2018 Jun;118(6):1001-1008. doi: 10.1055/s-0038-1645856. Epub 2018 May 3.

PMID:
29723874
4.

The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains.

Antman EM.

J Am Coll Cardiol. 2018 Apr 24;71(16):1752-1754. doi: 10.1016/j.jacc.2018.02.034. No abstract available.

PMID:
29673466
5.

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.

Cavallari I, Ruff CT, Nordio F, Deenadayalu N, Shi M, Lanz H, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Int J Cardiol. 2018 Apr 15;257:102-107. doi: 10.1016/j.ijcard.2018.01.065. Epub 2018 Feb 2.

PMID:
29395361
6.

American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics: A Presidential Advisory From the American Heart Association.

Antman EM, Creager MA, Houser SR, Warner JJ, Konig M; American Heart Association.

Circulation. 2017 Dec 12;136(24):e441-e447. doi: 10.1161/CIR.0000000000000551. Epub 2017 Nov 9. Review.

PMID:
29122813
7.

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.

Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF‐TIMI 48 Trial Investigators.

J Am Heart Assoc. 2017 Aug 11;6(8). pii: e006703. doi: 10.1161/JAHA.117.006703.

8.

NIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges.

Antman EM, Di Corleto PE, Freeman MW, Ganz T, Golan DE, Kitterman R, Loscalzo J, Low M, McKenna E, O'Connor AC, Palazzolo M, Parrish J, Reizes O, Ross RS, Vaughan C, Vince DG, Watts L; NIH Centers for Accelerated Innovations.

Nat Rev Drug Discov. 2017 Oct;16(10):663-664. doi: 10.1038/nrd.2017.131. Epub 2017 Aug 4. No abstract available.

PMID:
28775338
9.

The Introduction and Clinical Use of Cardiac-Specific Troponin Assays.

Antman EM.

Clin Pharmacol Ther. 2018 Jan;103(1):31-33. doi: 10.1002/cpt.773. Epub 2017 Jul 29.

PMID:
28755397
10.

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP.

J Am Heart Assoc. 2017 Jun 30;6(7). pii: e006035. doi: 10.1161/JAHA.117.006035.

11.

First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP.

Int J Cardiol. 2017 Oct 1;244:192-195. doi: 10.1016/j.ijcard.2017.05.098. Epub 2017 Jun 2.

PMID:
28625512
12.

Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs.

Antman EM.

Circulation. 2017 May 23;135(21):2062-2072. doi: 10.1161/CIRCULATIONAHA.117.027288. Review.

13.

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.

De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031.

14.

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Circ Arrhythm Electrophysiol. 2017 Jan;10(1). pii: e004267. doi: 10.1161/CIRCEP.116.004267.

15.

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.

Fanola CL, Giugliano RP, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman EM, Braunwald E.

Eur Heart J. 2017 Mar 21;38(12):888-896. doi: 10.1093/eurheartj/ehw565.

PMID:
28064150
16.

The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease.

Jones WS, Roe MT, Antman EM, Pletcher MJ, Harrington RA, Rothman RL, Oetgen WJ, Rao SV, Krucoff MW, Curtis LH, Hernandez AF, Masoudi FA.

J Am Coll Cardiol. 2016 Oct 25;68(17):1898-1907. doi: 10.1016/j.jacc.2016.07.781. Review.

17.

Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.

Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, Mercuri M, Antman EM, Morrow DA.

JAMA Cardiol. 2016 Dec 1;1(9):999-1006. doi: 10.1001/jamacardio.2016.3311.

PMID:
27706467
18.

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.

J Am Coll Cardiol. 2016 Sep 13;68(11):1169-1178. doi: 10.1016/j.jacc.2016.06.034.

19.

Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, but Much Work Remains.

Bohula EA, Antman EM.

JAMA. 2016 Sep 13;316(10):1045-7. doi: 10.1001/jama.2016.11940. No abstract available.

PMID:
27574716
20.

Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial.

Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY.

Circulation. 2016 Aug 2;134(5):378-91. doi: 10.1161/CIRCULATIONAHA.115.019949.

Supplemental Content

Loading ...
Support Center